Mark A. Currier

1.3k total citations
32 papers, 1.0k citations indexed

About

Mark A. Currier is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Mark A. Currier has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 21 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Mark A. Currier's work include Virus-based gene therapy research (26 papers), CAR-T cell therapy research (18 papers) and Herpesvirus Infections and Treatments (8 papers). Mark A. Currier is often cited by papers focused on Virus-based gene therapy research (26 papers), CAR-T cell therapy research (18 papers) and Herpesvirus Infections and Treatments (8 papers). Mark A. Currier collaborates with scholars based in United States, Netherlands and Italy. Mark A. Currier's co-authors include Timothy P. Cripe, Margaret H. Collins, Yonatan Y. Mahller, Lisa C. Adams, Alexander J. Towbin, James I. Geller, John M. Racadio, Keri A. Streby, Joe Conner and Rebecca A. Gillespie and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mark A. Currier

31 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark A. Currier United States	17	710	624	440	171	153	32	1.0k
Manel Cascalló Spain	25	1.2k 1.7×	906 1.5×	865 2.0×	84 0.5×	138 0.9×	49	1.5k
Jayson Hardcastle United States	10	572 0.8×	475 0.8×	353 0.8×	165 1.0×	237 1.5×	11	853
Heung Chong United Kingdom	18	758 1.1×	537 0.9×	874 2.0×	175 1.0×	498 3.3×	36	1.5k
Juan J. Rojas Spain	17	731 1.0×	575 0.9×	455 1.0×	63 0.4×	170 1.1×	23	967
Keiro Ikeda United States	10	570 0.8×	304 0.5×	366 0.8×	234 1.4×	54 0.4×	11	749
Justin C. Roth United States	14	392 0.6×	394 0.6×	403 0.9×	132 0.8×	156 1.0×	25	800
Y K Fung United States	17	288 0.4×	536 0.9×	834 1.9×	193 1.1×	148 1.0×	22	1.3k
Jennifer Coleman United States	11	447 0.6×	405 0.6×	266 0.6×	173 1.0×	140 0.9×	19	677
Tanja Hakkarainen Finland	23	949 1.3×	639 1.0×	847 1.9×	86 0.5×	109 0.7×	36	1.4k
D T Curiel United States	16	1.0k 1.4×	660 1.1×	1.0k 2.3×	65 0.4×	106 0.7×	21	1.5k

Countries citing papers authored by Mark A. Currier

Since Specialization

Citations

This map shows the geographic impact of Mark A. Currier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Currier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Currier more than expected).

Fields of papers citing papers by Mark A. Currier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Currier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Currier. The network helps show where Mark A. Currier may publish in the future.

Co-authorship network of co-authors of Mark A. Currier

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Currier. A scholar is included among the top collaborators of Mark A. Currier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Currier. Mark A. Currier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luo, Wen, Hoang Hai, Hongwen Zhu, et al.. (2024). Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy. Journal for ImmunoTherapy of Cancer. 12(9). e009726–e009726. 7 indexed citations

Hutzen, Brian, Chun‐Yu Chen, Pin-Yi Wang, et al.. (2024). Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors. Frontiers in Immunology. 15. 1384623–1384623. 1 indexed citations

Chen, Chun‐Yu, et al.. (2023). Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy. Molecular Therapy — Oncolytics. 29. 118–124. 12 indexed citations

Cripe, Timothy P., Brian Hutzen, Mark A. Currier, et al.. (2022). Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Science Advances. 8(28). eabm1890–eabm1890. 9 indexed citations

Wedekind, Mary Frances, Katherine E. Miller, Chun‐Yu Chen, et al.. (2021). Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 24(7). 102759–102759. 4 indexed citations

Streby, Keri A., Mark A. Currier, Mark Ranalli, et al.. (2019). First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Molecular Therapy. 27(11). 1930–1938. 49 indexed citations

Currier, Mark A., Justine Stehn, Duo Chen, et al.. (2017). Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs. Molecular Cancer Therapeutics. 16(8). 1555–1565. 36 indexed citations

Streby, Keri A., James I. Geller, Mark A. Currier, et al.. (2017). Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients. Clinical Cancer Research. 23(14). 3566–3574. 109 indexed citations

Orienti, Isabella, Mirella Falconi, Gabriella Teti, et al.. (2016). Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules. Pharmaceutical Research. 33(11). 2722–2735. 2 indexed citations

10.

Leddon, Jennifer L., Chun‐Yu Chen, Mark A. Currier, et al.. (2014). Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Molecular Therapy — Oncolytics. 1. 14010–14010. 31 indexed citations

11.

Wagner, Lars M., Hong Yin, David Eaves, Mark A. Currier, & Timothy P. Cripe. (2014). Preclinical evaluation of nanoparticle albumin‐bound paclitaxel for treatment of pediatric bone sarcoma. Pediatric Blood & Cancer. 61(11). 2096–2098. 23 indexed citations

12.

Currier, Mark A., Allyson Sholl, Kelly Crawford, et al.. (2013). VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. Molecular Therapy. 21(5). 1014–1023. 34 indexed citations

13.

Browne, Andrew, Jennifer L. Leddon, Mark A. Currier, et al.. (2011). Cancer Screening by Systemic Administration of a Gene Delivery Vector Encoding Tumor-Selective Secretable Biomarker Expression. PLoS ONE. 6(5). e19530–e19530. 6 indexed citations

14.

Currier, Mark A., et al.. (2010). VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Therapy. 17(7). 922–929. 32 indexed citations

15.

Wise‐Draper, Trisha M., Kathryn A. Wikenheiser‐Brokamp, Mark A. Currier, et al.. (2009). Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo. Cancer Research. 69(5). 1792–1799. 75 indexed citations

16.

Mahller, Yonatan Y., Sachin S. Vaikunth, Mark A. Currier, et al.. (2007). Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model. Molecular Therapy. 15(2). 279–286. 76 indexed citations

17.

Currier, Mark A., Lisa C. Adams, Yonatan Y. Mahller, & Timothy P. Cripe. (2005). Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Therapy. 12(4). 407–416. 37 indexed citations

18.

Parikh, Nehal S., Mark A. Currier, Yonatan Y. Mahller, et al.. (2004). Oncolytic herpes simplex virus mutants are more efficacious than wild‐type adenovirus Type 5 for the treatment of high‐risk neuroblastomas in preclinical models. Pediatric Blood & Cancer. 44(5). 469–478. 34 indexed citations

19.

Rice, Anna, Mark A. Currier, Lisa C. Adams, et al.. (2002). Ewing Sarcoma Family of Tumors Express Adenovirus Receptors and Are Susceptible to Adenovirus-Mediated Oncolysis. Journal of Pediatric Hematology/Oncology. 24(7). 527–533. 14 indexed citations

20.

Currier, Mark A., et al.. (2002). Differential Susceptibility of Pediatric Sarcoma Cells to Oncolysis by Conditionally Replication-Competent Herpes Simplex Viruses. Journal of Pediatric Hematology/Oncology. 24(6). 447–453. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact